Dyne Q1 net loss $120.9M; BLA for z-rostudirsen on track for Q2 2026

Dyne Therapeutics, Inc.

2026-Q1 EPS reported -$0.73

Net loss of $120.9M ($0.73 per share) vs $115.4M ($1.05) in Q1 2025.
Cash and marketable securities $972.2M; expected to fund operations into Q1 2028.
R&D expenses $100.9M (down from $106.4M); G&A $24.4M (up from $15.9M) due to launch prep.
Positive pre-BLA meeting with FDA; BLA submission for z-rostudirsen in exon 51 DMD on track for Q2 2026.
ACHIEVE trial enrollment target of 60 participants reached; Phase 3 HARMONIA trial for z-basivarsen in DM1 initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dyne Therapeutics, Inc. reported financial results for the first quarter of 2026.

Period: the first quarter of 2026
Result: reported results

Exact text from the filing

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today reported financial results for the first quarter of 2026 and recent business highlights.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dyne Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-215720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.